The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
1. Histological diagnosis of DLBCL\&LBCL
2. Planned treatment with guideline-based first-line therapy
3. Patient's consent
4. All genders, Patient age ≥ 18 years
5. Ability to consent
Exclusion Criteria:
1. Treatment with R-CHOP/-like regimens already started
2. Relationship of dependence/ direct employment with the investigator
3. Active HIV-infection
4. Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)
Primary outcome measure(s)
Progression-free Survival (PFS-2) with 95% confidence intervals — 2 years PFS is defined as the time from the day of inclusion into the observation trial through one of the following events, whichever comes first:
* Change of treatment due to response in iPET (PD - Progressive Disease)
* Disease progression
* Relapse
* Death due to any cause Patients without event at the time of analysis will be censored at the most recent date of disease assessment.
Trial sites (1)
Facility
City
Region
Status
Universitätsmedizin Göttingen
Göttingen
Lower Saxony
Recruiting
More University Medical Center Goettingen trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.